Isothermal Chain Reaction (ICR) Rapid and Early Detection of Pathogens for Sepsis Pont-of-Care Testing, Stratification, and Monitoring

等温链反应 (ICR) 快速、早期检测病原体,用于脓毒症即时护理测试、分层和监测

基本信息

  • 批准号:
    9200259
  • 负责人:
  • 金额:
    $ 30万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary Objectives: The long-term objective of this application is to develop novel products for routine point-of-care (POC) genetic testing, ranging from pathogen identification to early cancer detection by using an innovative biotechnology called, Isothermal Chain Reaction (ICR). ICR is a disruptive and enabling technology platform that will offer a new class of reagents relevant to biomedical research and medical healthcare. ICR does not require any enzymes, primers, nucleotides, master mixes, extension reactions, cDNA intermediates, or thermocycling. These benefits overcome constraints of PCR-based technologies by being resistant to enzyme inhibitors found in laboratory samples and clinical specimens, having higher specificity for rare mutations, and lowering reagent costs. ICR is anticipated to enable selective, rapid, and affordable biomarker detection without having to invest in costly instruments and labor-intensive sample preparation procedures. The envisioned products will be assays, panels, and kits for the early detection of infectious and genetic diseases in non-laboratory settings. Specific Aims: 1. Development of ICR probes to sepsis target sequences: We will design and develop ICR assays to rapidly and isothermally detect synthetic target sequences associated with sepsis in a mixed population of templates in less than 10 minutes under isothermal conditions, without enzymes, primers, nucleotides, or master mixes. 2. Identification of known sepsis pathogens in blood samples: We will use ICR assays from Specific Aim 1 to identify known sepsis pathogens from retrospective blood samples. ICR results will be benchmarked to blood cultures to demonstrate the feasibility of using ICR for rapid early detection of sepsis biomarkers. 3. Identification of unknown sepsis pathogens in blood samples: We will use ICR assays from Specific Aim 1 to identify unknown sepsis pathogens from retrospective blood samples. ICR results will be benchmarked to blood cultures to demonstrate the feasibility that ICR has enhanced selectivity to detect pathogens missed by blood culture methods, and ICR is more amenable to point-of-care sepsis testing. Impact: Accomplishing the Specific Aims could significantly impact rapid and early detection of sepsis pathogens when therapeutic interventions are much more effective, and enable routine clinical testing and screening of the disease to improve clinical triage decisions, routine monitoring, and treatment outcomes.
项目摘要 目的: 本申请的长期目标是开发用于常规床旁(POC)遗传学检查的新产品。 检测,从病原体鉴定到使用创新生物技术进行早期癌症检测, 等温链反应(Isothermal Chain Reaction,ICR)ICR是一个颠覆性的支持技术平台, 与生物医学研究和医疗保健相关的新型试剂。ICR不需要任何 酶、引物、核苷酸、主混合物、延伸反应、cDNA中间体或热循环。 这些益处克服了基于PCR技术的限制,因为它们对发现的酶抑制剂具有抗性。 在实验室样本和临床标本中,对罕见突变具有更高的特异性, 成本ICR有望实现选择性,快速和负担得起的生物标志物检测,而无需投资 昂贵的仪器和劳动密集型的样品制备程序。设想的产品将是 用于在非实验室环境中早期检测传染病和遗传病的检测试剂盒、检测板和试剂盒。 具体目标: 1.针对脓毒症靶序列的ICR探针的开发:我们将设计和开发ICR检测, 并等温检测与败血症相关的合成靶序列, 在等温条件下,在不到10分钟的时间内,在没有酶、引物、核苷酸或 大师混音 2.血液样本中已知脓毒症病原体的鉴定:我们将使用特定目标1至 从回顾性血液样本中鉴定已知脓毒症病原体。将对ICR结果进行基准测试, 血培养证明使用ICR快速早期检测脓毒症生物标志物的可行性。 3.血液样本中未知脓毒症病原体的鉴定:我们将使用来自Specific Aim 1的ICR检测试剂盒 从回顾性血液样本中鉴定未知的脓毒症病原体。ICR结果将是 以血培养为基准,以证明ICR增强了检测选择性的可行性 血液培养方法遗漏的病原体,ICR更适合于护理点败血症检测。 影响: 实现特定目标可以显著影响脓毒症病原体的快速和早期检测 当治疗干预更加有效,并使常规临床测试和筛查成为可能时, 以改善临床分诊决策、常规监测和治疗结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ricardo Mancebo其他文献

Ricardo Mancebo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ricardo Mancebo', 18)}}的其他基金

Development of a handheld rapid air sensing system to monitor and quantify SARS-CoV-2 in aerosols in real-time
开发手持式快速空气传感系统,实时监测和量化气溶胶中的 SARS-CoV-2
  • 批准号:
    10854070
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
Development of a handheld rapid air sensing system to monitor and quantify SARS-CoV-2 in aerosols in real-time
开发手持式快速空气传感系统,实时监测和量化气溶胶中的 SARS-CoV-2
  • 批准号:
    10273983
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:

相似海外基金

SBIR Phase I: Automated One-Hour Testing for Bacteremia and Antibiotic Sensitivity
SBIR 第一阶段:一小时自动检测菌血症和抗生素敏感性
  • 批准号:
    2304069
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
Epigenomic Mechanisms & Contextual Immunity in Persistent MRSA Bacteremia
表观基因组机制
  • 批准号:
    10551708
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
The contribution of respiratory burst to antibiotic failure in Staphylococcus aureus bacteremia
呼吸爆发对金黄色葡萄球菌菌血症抗生素失效的影响
  • 批准号:
    10666777
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
Genetic Analyses of bacteremia non-typhoidal Salmonella
非伤寒沙门氏菌菌血症的遗传分析
  • 批准号:
    10580145
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
Task A58: Therapeutic Testing in Murine Models of Bacterial Thigh, Lung, Bacteremia and Peritonitis Infections
任务 A58:细菌性大腿、肺、菌血症和腹膜炎感染的小鼠模型的治疗测试
  • 批准号:
    10655826
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Task A58: Therapeutic Testing in Murine Models of Bacterial Thigh, Lung, Bacteremia and Peritonitis Infections
任务 A58:细菌性大腿、肺、菌血症和腹膜炎感染的小鼠模型的治疗测试
  • 批准号:
    10590044
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Task A58: Therapeutic Testing in Murine Models of Bacterial Thigh, Lung, Bacteremia and Peritonitis Infections
任务 A58:细菌性大腿、肺、菌血症和腹膜炎感染的小鼠模型的治疗测试
  • 批准号:
    10475953
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Task A58: Therapeutic Testing in Murine Models of Bacterial Thigh, Lung, Bacteremia and Peritonitis Infections
任务 A58:细菌性大腿、肺、菌血症和腹膜炎感染的小鼠模型的治疗测试
  • 批准号:
    10551060
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Task A58: Therapeutic Testing in Murine Models of Bacterial Thigh, Lung, Bacteremia and Peritonitis Infections
任务 A58:细菌性大腿、肺、菌血症和腹膜炎感染的小鼠模型的治疗测试
  • 批准号:
    10590048
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Randomized Controlled Clinical Trial
菌血症临床有效性实际需要的抗生素长度(平衡):一项随机对照临床试验
  • 批准号:
    448738
  • 财政年份:
    2020
  • 资助金额:
    $ 30万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了